Tonix Pharmaceuticals Holding Corp. (TNXP) is a research-driven biopharmaceutical company focused on discovering, licensing, developing, and commercializing innovative treatments for a wide range of health conditions. The company specializes in small molecules and biologics which offer significant improvements over existing therapies, or address gaps in current treatments. Its headquarters are located in New York and it is listed on the NASDAQ, under the ticker symbol TNXP.
Most of the company's research and development efforts are concentrated on the central nervous system and immunity, with in-progress therapeutic solutions for conditions like post-traumatic stress disorder (PTSD), fibromyalgia, and episodic tension-type headache. It also develops therapies for organ transplantation, epilepsy, and even COVID-19.
Tonix focuses on improving the pharmaceutical characteristics and safety profile of these advanced treatments. Its mission is to develop next-generation medicines that can be transformative and bring relief to people suffering from debilitating diseases. While the company's core belief is in the power of science, it also strives to ensure the patient's best interests are always accounted for, and its work is driven by integrity, excellence, and innovative thinking.
Tonix's lead program is TNX-102 SL, which is currently in Phase 3 development as a bedtime treatment for fibromyalgia, and for PTSD. The company already achieved significant milestones with respect to these diseases. For example, TNXP was granted Breakthrough Therapy designation by the FDA for TNX-102 SL for the treatment of PTSD.
Another promising treatment under study by Tonix is TNX-801, a potential smallpox-preventing vaccine. The company is also exploring novel treatments for COVID-19 – the most advanced being TNX-1800, a potential vaccine, and TNX-3500 (sangivamycin).
While Tonix Pharmaceuticals Holding Corp. operates in a highly competitive and risky industry, its focus on both common and niche health areas, along with its innovative approach to treatment development, has set it apart from others in the industry. It has earned a reputation for its commitment to enhancing the quality of life for patients while creating robust value for shareholders.
The success of Tonix is reflected in its growth and cutting-edge research, reinforcing its potential as a primary player in the biotechnology sector. Celebrated by patients, medical professionals, and investors alike, it is a company that is truly poised to make a lasting impact on global health.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Tonix Pharmaceuticals Holding Corp. (TNXP) reported its Q3 2026 financial results, with a diluted loss of $2.89 per share, wider than analysts' expectations. However, the company's revenue of $17.2 million surpassed Wall Street forecasts by 5.6% and showed a significant 424.3% year-over-year increase. TONMYA, a key product, contributed $15.0 million to the quarter's revenue.
Tonix Pharmaceuticals announced its financial results for the third quarter of 2026, reporting approximately $15 million in net sales for TONMYA®, a 37% increase from the previous quarter. The company also highlighted its strong cash position of $163 million and strategic focus on expanding TONMYA's market presence, while advancing its core clinical programs for major depressive disorder, Lyme disease prevention, and kidney transplant rejection. Despite a net loss of $53.3 million for the quarter, Tonix increased its sales force and expanded payer access for TONMYA.
Tonix Pharmaceuticals has appointed George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation, effective October 30, 2026. In this role, Lederman will lead AI initiatives to enhance operational efficiency and manage costs, as well as oversee business development, including evaluating partnerships and licensing opportunities to advance clinical programs and share development costs. Dr. Lederman brings extensive experience from Aliaxis and McKinsey & Company, where he focused on corporate strategy, operational transformation, and applied artificial intelligence.
This article provides a price-driven insight for Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), indicating weak sentiment across all horizons and supporting a short bias. It outlines three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strength, support, and resistance levels for near-term, mid-term, and long-term horizons.